Momordica charantia L., also known as bitter melon, has been shown to ameliorate obesity and insulin resistance. However, metabolic changes regulated by M. charantia in obesity are not clearly understood. In this study, serums obtained from obese and M. charantia-treated mice were analyzed by using gas and liquid chromatography-mass spectrometry, and multivariate statistical analysis was performed by Orthogonal partial least squares discriminant analysis. The results from this study indicated that body weight fat and insulin levels of obese mice are dramatically suppressed by 8 weeks of dietary supplementation of M. charantia. Metabolomic data revealed that overproductions of energy and nutrient metabolism in obese mice were restored by M. charantia treatment. The antiinflammatory and inhibition of insulin resistance effect of M. charantia in obesity was illustrated with the restoration of free fatty acids and eicosanoids. The findings achieved in this study further strengthen the therapeutic value of using M. charantia to treat obesity.
INTRODUCTION
The prevalence and incidence of obesity have become a major public health problem over the past decades (Kopelman, 2000) . Obesity is an important risk factor for many chronic diseases (Gomes et al., 2013; Hjartaker et al., 2008; Matsuda and Shimomura, 2014; Yilmaz and Younossi, 2014) . Therefore, prevention and therapy of obesity would be beneficial for decreasing disease desirable or therapeutic programs early in life (Farook et al., 2015; Loprinzi et al., 2015) .
Momordica charantia L. (Cucurbitaceae), also known as bitter melon, bitter gourd, or balsam pear, is a climbing shrub that is widely grown in Asia, Africa, and Caribbean. Its fruit was taken as a culinary vegetable in many countries and also used as a traditional medicine for various diseases in Asian and South American countries (Alam et al., 2015) . This plant is mostly used to treat diabetes in different countries around the world (Fuangchan et al., 2011) . M. charantia is also used for the treatment of various other pathological conditions such as dysmenorrhea, eczema, emmenagogue, galactagogue, gout, jaundice, kidney stone, leprosy, leucorrhea, piles, pneumonia, psoriasis, rheumatism, and scabies (Grover and Yadav, 2004) .
Recent studies suggested that M. charantia has the capacity to prevent high-fat diet-induced obesity and hyperlipidemia (Balazs, 2010; Krawinkel and Keding, 2006; Singh et al., 2011) . The extract of M. charantia may modulate fat metabolism kinases such as AMPactivated protein kinase, genes, and nuclear factors like peroxisome proliferator-activated receptors, Liver X receptors, and peroxisome proliferator-activated receptor gamma coactivator 1-alpha in liver and skeletal muscle and affected adipocyte differentiation (Alam et al., 2015) . However, metabolic profiling changes regulated by M. charantia on obesity are still unclear.
Metabolomics refers to global investigation of metabolites in biological systems (Gil et al., 2015; Madsen et al., 2010; Zhang et al., 2012) . It has been proven to be of great help to the study of obesity , to identify early and differential metabolic markers of obesity, and to understand mechanism of obesity occurrence and progression (Duggan et al., 2011; Jung et al., 2012; Kim et al., 2009) . Previous metabolomic studies have identified a few molecules to discriminate lean from individual subjects with obesity (Ding and Mak, 2015; Kim et al., 2010; Oberbach et al., 2011) .
In this study, serums from mice fed with normal-chow diet (NCD) and high-fat diet (HFD) were analyzed by gas and liquid chromatography-mass spectrometry (GC/MS and LC/MS). Metabolomic analysis demonstrated subtle metabolic changes between HFD and NCD mice. Furthermore, the administration of M. charantia aqueous extract (MCAE) restored specific metabolic perturbations in obese mice. Our finding clarified that M. charantia showed antiinflammatory effect, increased insulin sensitivity, and decreased insulin resistance. This study provided further evidence to support the therapeutic value of M. charantia for obesity.
MATERIALS AND METHODS
Chemicals and reagents. N-(9-Fluorenylmethoxycarbonyl)-glycine and N-methyl-N-trimethyl-silyltrifluoroacetamide were purchased from J&K Scientific Company (Shanghai, China). Formic acid, pyridine, and high-performance LC-grade methanol were obtained from Shanghai ANPEL Scientific Company (Shanghai, China). The NCD and HFD were purchased from Shuangshi Laboratory Animal Feed Science Co., Ltd (Suzhou, China).
Extract preparation and analysis. Air-dried whole fruits of M. charantia (1 kg) were pulverized into powder and extracted triple by 5 L of boiling water for 1 h. After filtration, the extracts were combined and freeze-dried, affording 250 g of aqueous extract. A solution of 1 mg/mL of MCAE in water was analyzed by LC-MS measurement. An Agilent Eclipse plus C18 (2.1 × 500 mm, 1.8 μm) was used with the column temperature held at 35°C. The analysis was carried out at a flow rate of 0.4 mL/min with mobile phases consisting of 0.1% acetic acid (A) and acetonitrile (B). The gradient elution was as follows: 0-2 min, 5-10% (B); 2-6 min, 10-30% (B); 6-20 min, 30-95% (B); 20-22 min, 95-100% (B); 22-25 min, 100% (B); and 25-28 min, 100-5% (B). The main peaks in chromatography were identified by comparing MS data with literature values. The relative concentrations of identified compounds were calculated by comparison of each peak area with total peak area.
Animal handling procedure. Animal experiments were performed according to the Institutional guidelines for Animal Care and Use Committee of Chinese Academy of Sciences. All these protocols were reviewed and approved by the Institutional Review Board of Shanghai Institutes for Biological Sciences. Five-week-old male C57/B6 mice were purchased from Beijing Weitong Lihua Laboratory Animal Co., Ltd. After 1 week of acclimation, the mice were randomly divided into four groups (n = 10/group) and fed with NCD or HFD for 8 weeks to develop experimental obesity, which could be considered as a double blind trial. Afterward, the NCD and HFD control groups were orally administered distilled water each day for 6 weeks. The other two groups received 1.0 g/kg/day of MCAE. The animals were weighted, and their body weight was calculated every 2 weeks. At the end of the feeding period, blood was drawn from the abdominal aorta into a vacuum tube and incubated at room temperature for 1 h prior centrifugation for serum collection. The serum was frozen at À80°C until further analysis.
Biochemical analysis. Serum concentration of total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride (TG) were determined enzymatically by using commercial kits (BioClinical System, China). The serum concentration of low-density lipoprotein cholesterol combined was calculated by subtracting the HDL cholesterol concentration from the total cholesterol concentration. The serum insulin levels were determined by using an insulin mouse ELISA kit (KMC2281; Novex, USA).
Sample preparation. Prior to analysis, the serum samples were thawed at 4°C. In total, 50 μL of serum was added into a vial and extracted with 200 μL of cold methanol containing 10 μg/mL of N-(9-fluorenylmethoxycarbonyl)-glycine as internal standard, followed by vigorous vortex for 3 min and then by centrifugation at 14 000g for 10 min at 4°C. Supernatant was collected and divided into two parts: 70 μL for GC/MS analysis and the other 70 μL for LC/MS analysis directly.
Gas chromatography-mass spectrometry derivatization was based on our earlier method . Briefly, 70 μL of supernatant was dried under nitrogen and then derivatized with 150 μL of methoxyamine in pyridine (5 mg/mL) at 37°C for 2 h and followed by 150 μL of N-methyl-N-trimethyl-silyl-trifluoroacetamide (37°C × 16 h). After centrifugation (4°C, 3824g × 1 min), 1 μL of the supernatant was injected into GC/MS in the splitless mode.
GC/MS and LC/MS analyses. Gas chromatographymass spectrometry analysis was performed on a Thermo DSQ GC/MS system equipped with a fused-silica capillary column HP-5MSI (30 m × 0.25 mm i.d., 0.25 μm film thickness). The injector was kept at 250°C. A 1 μL of sample was splitlessly injected for each individual analysis. Helium was used as the carrier gas with a constant flow rate 1 mL/min through the column. The GC oven temperature was maintained at 70°C for 1 min, and then increased to 250°C at a rate of 10°C/min, and further increased at 25°C/min to 300°C and held for 6 min. The transfer line temperature was kept at 280°C. Detection was achieved by using MS in electron impact mode (70 eV) and full scan monitoring (m/z 50-550). The temperature of the ion source was set at 230°C, and the quadrupole was set at 150°C. The compounds were identified by comparison of mass spectra and retention time with those of reference standards and those available in libraries (NIST 0.5; Thermo Fisher Scientific).
Liquid chromatography-mass spectrometry analysis was performed on a high-performance LC system 1200 (Agilent Technologies, Santa Clara, USA) coupled to a 6520 quadrupole time of flight mass detector equipped with an electrospray ionization source in positive and negative modes. The separation was performed on an Agilent rapid resolution HT Zorbax SB-C18 column (2.1 × 50 mm, 1.8 μm, Agilent) at a column temperature of 50°C. The mobile phases A (water with 0.1% formic acid) and B (acetonitrile with 0.1% formic acid) were employed in the positive mode, whereas C (water with 0.1% acetic acid) and D (acetonitrile with 0.1% acetic acid) were used in the negative mode. The gradient program was as follows: 0-9 min, 5-45% B (or D); 9-15 min, 45-100% B (or D); and 15-18 min, 100% B (or D); 18-20 min, 100-5% B (or D). The flow rate was set at 0.4 mL/min. A 10 μL of aliquot of sample was injected for each. Mass data were collected between m/z 100 and 1000 at a rate of 2 scan/s. The ion spray voltage was set at 4000 V, and the heated capillary temperature was maintained at 350°C. The drying gas and nebulizer nitrogen gas flow rates were 12.0 L/min and 50 p.s.i., respectively. MS-MS analysis was used to study the structure of potential biomarkers. In this section, we used three different collision energies at 10, 20, and 40 V for each target ion.
Data preprocessing and analysis. The LC/MS and GC/MS data were converted from proprietary to mzData format and pretreated by the open-source software MZMINE for peak detection, peak alignment, and peak area normalization in each dataset (Pluskal et al., 2010) . Multivariate analysis was carried out by using SIMCA-P (Umetrics, Sweden). Orthogonal partial least squares discriminant analysis (OPLS-DA) was employed to distinguish samples according to their conditions (Ho et al., 2013) . In OPLS-DA analysis, the value of R 2 Y describes how well the data in the training set are mathematically reproduced, ranging between 0 and 1, where 1 indicates a model with a perfect fit. Models with a Q 2 value greater than or equal to 0.5 are generally considered to have good predictive capability. Univariate statistical tests (paired t-test and nonparametric tests) and receiver operating characteristic were performed on SPSS software. p-values less than 0.05 and receiver operating characteristic higher than 0.90 were considered significant. The heatmap of significant changed metabolites was conducted by using MULTIEXPERIMENT VIEW version 4.6.1 (www.tm4.org).
Metabolite identification. Potential biomarkers were identified based on our previously described methods (Ho et al., 2013) . In brief, NIST 11 mass spectral library was used to identify metabolites in GC-MS spectra according to retention index and mass-spectral similarity (>80%) match. In LC/MS analysis, the metabolites were identified on the basis of accurate mass, MS/MS information, and retention time by matching features in databases Human Metabolome Database (http://www. hmdb.ca), METLIN (http://metlin.scripps.edu), and Lipid MAPS (http://www.lipidmaps.org). Finally, the structure of metabolites was confirmed by using commercial standards. 
RESULTS

LC-MS-based fingerprint of MCAE
In this study, we first carried out the qualitative and quantitative analyses of main components in the aqueous extract of M. charantia. A total of 21 main peaks in chromatography were identified, including momordicoside A-E, F1, F2, G, K-M, and P; goyaglycoside A-G; and cucurbitacin B and K (Fig. E1) . We also quantitative analyzed these compounds. The retention time, m/z, and relative concentration for these compounds are summarized in Table E1 .
M. charantia-altered animal characteristics
In the beginning, four group mice were statistically identical in body weights (23.3 AE 1.27 g). After 10 weeks' feed, the average body weight of the HFD group was notably higher than that of the NCD group (33.6 AE 2.18 g vs 29.6 AE 1.74 g, p < 0.05). The average body weight of MCAE-treated HFD mice was obviously lower than that of the HFD subjects (40.7 AE 2.07 g vs 46.4 AE 2.36 g, p < 0.05) after 8 weeks' dietary supplementation of MCAE. However, there was no significant difference between the MCAE-treated NCD mice and the NCD control animals (Fig. 1A) .
The level of serum insulin for the mice in the HFD group was significantly higher than that in the normal group (p < 0.05). The insulin levels of the mice fed with MCAE were lower than that in the HFD group (p < 0.05) and comparable with the level found in the normal group (Fig. 1B) . Additionally, serum TG was the highest in HFD mice, but there was no significant difference between the NCD and NCD/MCAE groups. The total cholesterol did not differ among the four groups. However, the concentration of HDL cholesterol was higher in NCD than in HFD groups, and administration of MCAE led to a slightly elevation of HDL in HFD mice. The low-density lipoprotein cholesterol level in the HFD group was slightly higher than in other groups (Fig. 1C) .
Altered serum metabolites in experimental obesity
We performed metabolite profiling in serum from NCD and HFD mice by using GC/MS and LC/MS. The OPLS-DA model analysis distinguished the HFD group from the NCD group clearly ( Fig. 2A and B) , with strong modeling fit R 2 Y values of 0.979 (GC/MS) and 0.956 (LC/MS), as well as good prediction Q 2 values of 0.826 (GC/MS) and 0.755 (LC/MS). Statistical analysis identified that multiple metabolites enabled discrimination of obese animals from healthy control animals. These metabolites revealed major alteration in metabolism on experimental murine. Fold changes of these metabolites are depicted in the heatmap for each group (Fig. 3) .
Altered energy metabolism was found in HFD mice, with substantial decreases in lactate, malate, and creatinine. Fatty and organic acids, such as butanedioic acid, tetradecanoic acid, palmitic acid, stearic acid, linoleic acid, and arachidonic acid, were elevated in HFD mice when compared with the controls. On the other hand, oxidation products of arachidonic acid, such as 9-hydroxyeicosatetraenoic acid (9-HETE) and 15-HETE, were upregulated in HFD mice. Serum bile acid and carbohydrate levels were also significantly elevated in HFD mice, such as cholesterol, cholic acid, deoxycholic acid, and taurocholic acid, as well as glucose, mannose, galactose, and trehalose. Interestingly, free amino acid analysis showed remarkable changes in individual amino acids. As opposed to controls, HFD mice had significantly higher levels of many amino acids, such as valine, leucine, asparagines, proline, histidine, and serine, but lower levels of glycine, arginine glutamine, and alanine. Alterations in lipids were also detected in obese mice, with increase of phosphatidylcholines (PCs), diglycerides (DGs), and TGs. Detailed 
M. charantia does not alter metabolite profiles in NCD mice
Principal component analysis on our experimental data from GC/MS and LC/MS measurements indicates no distinctive differences between untreated NCD mice (NCD) and MCAE-treated NCD mice (NCD/MCAE). Moreover, OPLS-DA revealed little difference in serum metabolite profiles between NCD and NCD/MCAE, as indicated by poor modeling scores R 2 Y (0.56 and0.79) and predictive Q 2 values (0.126 and 0.0047) detected by GC/MS and LC/MS (Fig. E3 ). In line with these findings, M. charantia did not alter the animal characteristics of NCD mice.
M. charantia reverses metabolic changes in experimental obesity
In OPLS-DA analysis (Fig. 2) , M. charantia-treated experimental obesity (HFD/MCAE) shifted from HFD, with strong R 2 Y (0.811 and 0.962) as well as Q 2 (0.708 and 0.632) values. On the contrary, there are no distinctive differences in NCD and MCAE-treated NCD (NCD/MCAE). An overview of potential obese biomarker changes revered by M. charantia was represented in a heatmap (Fig. 3) . M. charantia halted the elevation in fatty acids, eicosanoids, carbohydrates, and amino acids in obesity. In contrast, M. charantia reversed the falls in serum malate, arginine, and glutamine in obese mice.
DISCUSSION
Metabolomics, especially MS-based metabolomics, offers quantitative analyses with high selectivity and sensitivity, which has been used in many disciples (Winder et al., 2011) . M. charantia has been reported to exert therapeutic effect on obesity. In this study, we employed metabolomic approach to investigate the antiobesity effect of M. charantia on high-fat diet-induced obese mice. These metabolic signatures, coupled with good predictive values of the mathematical modeling, revealed major alterations in serum metabolism in an experimental murine model of obesity that was substantially reversed by M. charantia. These alterations of serum metabolome in experimental obesity and reversal effects by M. charantia are illustrated in Fig. 4 .
Obesity is a physiological feature that excess body fat has accumulated to the extent. In the present study, we found the significant increase in average body weight, serum insulin level, and TG level in the HFD group when compared with the NCD group. Meanwhile, the antiobesity activity of M. charantia was evaluated by administration of MCAE on HFD and NCD mice. The result indicated that M. charantia remarkably reduced body weight, serum insulin, and TG level in HFD mice. But these biochemical parameters in NCD mice were undisturbed by M. charantia treatment (Fig. 1) . Indeed, a number of animal and human studies have showed positive associations between consumption of M. charantia and loss body weight (Hasani-Ranjbar et al., 2009; Xu, X. et al., 2015) . Therefore, it suggested that M. charantia exhibits potential antiobesity activity. However, large trials possibly adhering to the cohort guidelines are needed to firmly establish the clinical relevance of M. charantia in obesity, and that future trials should be conducted with the same reliable attention as normally performed for conventional medicines (Izzo et al., 2016) .
We further performed metabolomic analysis on serum derived from NCD and HFD mice, together with MCAE-treated NCD and HFD animals. OPLS-DA analysis showed the differences in serum metabolite profiles among normal, obese, and MCAE-treated mice (Fig. 2) . Statistical analysis identified that several metabolites altered by induced HFD were moderated by treated MCAE, including amino acids, fatty acids, carbohydrates, and lipids. Based on these metabolites, the metabolic pathway associated with HFD and M. charantia intake was illustrated in Fig. 4 , adapted from a recent study (Kim et al., 2011) .
The changes of lipid metabolism intermediates were directly or indirectly involved in fat accumulation of subjects with obesity (van der Veen et al., 2012) . In this study, we found that the levels of linoleic acids, octadecanoic acid, oleic acid, and arachidonic acid were increased in HFD mice, agreeing with an earlier finding (Boden, 2008) . Moreover, plasma fatty acids arise from adipose tissue that is increased in obesity and increase in obese individuals leading to the insulin resistance (Boden, 2011) . Thereout, the high fatty acid levels in HFD mice were downregulated by MCAE treatment, indicating that M. charantia can restore the disorder of fatty acid metabolism and prevent insulin resistance of obesity. Similar to the findings of another study (Hasani-Ranjbar et al., 2009) , we noted higher concentration of PCs, DGs, and TGs in the HFD group when compared with the NCD group. We also noted the decrease of these lipids in HFD/MCAE mice, and then these data validated and confirmed the earlier observations that M. charantia can reduce fat accumulation in obesity and ameliorate the disorder of lipid metabolism in obesity (Bao et al., 2013) .
Obesity is also associated with elevated levels of proinflammatory cytokines and chemokines in circulation and in tissue (Tataranni and Ortega, 2005) . 9-HETE and 15-HETE have been well recognized as inflammatory mediators associated with obesity (Pickens et al., 2015) . In this study, we observed the increase of 9-HETE and 15-HETE in HFD mice and decrease in HFD/MCAE mice. This result implied that M. charantia has potential antiinflammatory properties on obesity.
Branched-chain amino acid is suggestive of increased insulin resistance in animal and human obesity (Kim et al., 2010; McCormack et al., 2013) . In our study, histidine, isoleucine, serine, leucine, and valine were found increased in obese mice, which is consistent with previous study (Kim et al., 2010; Newgard et al., 2009) . On the other hand, the upward trends of branched-chain amino acids in obese mice were suppressed by MCAE treatment. These results provided further evidence that M. charantia has sensitization to insulin and prevent insulin resistance.
The energy metabolism was also dysregulated in obesity (Goran, 2000) . Malate is a metabolic product from carbohydrate breakdown via the tri-carboxylic cycle to provide additional energy in the form of adenosine triphosphate. In the present study, malate level was observed to be declined in HFD mice, indicating consistent impairment of energy metabolism in obesity. We identified the involvement of the glucose-alanine metabolic pathway in obesity, with decreases in alanine, glutamine, and arginine. The glucose-alanine cycle is an alternative energy-producing metabolic pathway that is activated during anaerobic cellular respiration (Viru et al., 1994) . In a similar fashion, considerable reductions in the downstream metabolite-arginine were also noted in experimental obesity. The levels of malate, arginine, and lactate in HFD/BME group were restored by bitter melon, suggesting that bitter melon impacts energy metabolism in obesity.
The disorder of glucose metabolism is common in obesity. Similar results have been reported in studies of human and animal models (Parekh and Anania, 2007) . In addition, bile acids were also noted to increase in obese mice (Reddy et al., 1988) . In this study, M. charantia inhibited the rising of carbohydrates and bile acids in HFD mice. It demonstrated that M. charantia can renovate glucose and cholesterol metabolism in obesity.
In conclusion, the collective results in this study provided useful information to better understand obesity-related metabolism. In addition, we revealed that M. charantia possesses considerable restorative actions on serum metabolism in experimental obesity. While M. charantia can suppress fat accumulation and insulin resistance, it did not affect metabolic profiles in normal mice. These metabolomic data further strengthen the therapeutic value of M. charantia for obesity.
